达比加群酯对非瓣膜性房颤导管消融围术期抗凝疗效和安全性的Meta分析

郑炜平; 陈锋; 李永坤; 林开阳; 江芸

doi:10.13308/j.issn.2095-9354.2016.05.007

PDF(1481 KB)

实用心电与临床诊疗 ›› 2016, Vol. 25 ›› Issue (5) : 334-341. DOI: 10.13308/j.issn.2095-9354.2016.05.007

论著

达比加群酯对非瓣膜性房颤导管消融围术期抗凝疗效和安全性的Meta分析

作者信息 +

Efficacy and safety of dabigatran perioperative anticoagulation for patients undergoing catheter ablation of nonvalvular atrial fibrillation: a Metaanalysis

Author information +

文章历史 +

摘要

目的系统评价达比加群酯对非瓣膜性房颤导管消融围术期的抗凝疗效和安全性。方法计算机检索PubMed、EMbase、The Cochrane Library（2016年第2期）、CMB、知网、万方和维普数据库，搜集有关房颤导管消融围术期使用达比加群酯和华法林抗凝治疗的随机对照及非随机对照的研究文献，由两位评价员独立筛选文献、提取资料和评价纳入研究的偏倚风险后，采用RevMan 5.3软件进行Meta分析。结果最终纳入23个研究、共7 673例患者。Meta分析结果显示：达比加群酯组脑卒中或短暂性脑缺血发生率与华法林组无明显区别[OR=1.0，95%CI：0.60~1.68，P=0.99]，大出血事件发生率无明显区别[OR=0.79，95%CI:0.52~1.19，P=0.25]，小出血事件发生率显著降低[OR=0.71，95%CI:0.57~0.87，P=0.001]。结论达比加群酯在房颤导管消融围术期抗凝疗效及大出血并发症的发生率上与华法林无明显区别，小出血并发症的发生率较华法林降低。

Abstract

Objective To systematically evaluate the efficacy and safety of dabigatran perioperative anticoagulation for patients undergoing catheter ablation of nonvalvular atrial fibrillation. Methods We collected research literature of randomized controlled trials (RCTs) or nonRCTs about perioperative anticoagulation for patients undergoing catheter ablation of nonvalvular atrial fibrillation from databases including PubMed, EMbase, The Cochrane Library (Issue 2, 2016), CMB, CNKI, Wanfang and VIP with computer. Two evaluators independently screened literatures, extracted data and assessed the bias risk of included studies, and then performed Metaanalysis by using software of RevMan 5.3. Results A total of 23 studies involving 7 673 patients were finally enrolled in Metaanalysis. It showed no statistically significant difference in the incidence of cerebral apoplexy or transient cerebral ischemia between dabigatran and warfarin groups(OR=1.0, 95%CI：0.60-1.68, P=0.99), and so did the incidence of hemorrhoea event(OR=0.79, 95%CI：0.52-1.19, P=0.25). The incidence of minor hemorrhoea event in dabigatran group was significantly decreased than that in warfarin group(OR=0.71, 95%CI：0.57-0.87, P=0.001). Conclusion There was no significant difference in the efficacy of perioperative anticoagulation for patients undergoing catheter ablation of nonvalvular atrial fibrillation and incidence of complication of hemorrhoea between dabigatran and warfarin. For patients taking dabigatran, the incidence of complication of minor hemorrhoea is reduced if compared with those taking warfarin.

导出引用

郑炜平, 陈锋, 李永坤, 等. 达比加群酯对非瓣膜性房颤导管消融围术期抗凝疗效和安全性的Meta分析[J]. 实用心电学杂志, 2016, 25(5): 334-341 https://doi.org/10.13308/j.issn.2095-9354.2016.05.007

ZHENG Wei-Ping, CHEN Feng, LI Yong-Kun, et al. Efficacy and safety of dabigatran perioperative anticoagulation for patients undergoing catheter ablation of nonvalvular atrial fibrillation: a Metaanalysis[J]. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2016, 25(5): 334-341 https://doi.org/10.13308/j.issn.2095-9354.2016.05.007

参考文献

[1] Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention[J]. Circulation, 2003,108(6):711-716.

[2] 黄从新, 张澍, 黄德嘉, 等. 心房颤动：目前的认识和治疗建议—2015[J]. 中华心律失常学杂志, 2015,19(5):321-384.

[3] Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin[J]. Circulation, 2013,128(21):2325-2332.

[4] Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist naive and experienced cohorts with atrial fibrillation[J]. Circulation, 2010,122(22):2246-2253.

[5] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009,361(12):1139-1151.

[6] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012,33(21):2719-2747.

[7] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014,64(21):e1-e76.

[8] Armbruster HL, Lindsley JP, Moranville MP, et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation[J]. Ann Pharmacother, 2015,49(3):278-284.

[9] Arshad A, Johnson CK, Mittal S, et al. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study[J]. Pacing Clin Electrophysiol, 2014,37(6):665-673.

[10] Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2013,6(3):460-466.

[11] Haines DE, MeadSalley M, Salazar M, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation[J]. J Interv Card Electrophysiol, 2013,37(3):233-239.

[12] Imamura K, Yoshida A, Takei A, et al. Dabigatran in the periprocedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay[J]. J Interv Card Electrophysiol, 2013,37(3):223-231.

[13] Kaiser DW, Streur MM, Nagarakanti R, et al. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter[J]. J Interv Card Electrophysiol, 2013,37(3):241-247.

[14] Kaseno K, Naito S, Nakamura K, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation[J]. Circ J, 2012,76(10):2337-2342.

[15] Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation[J]. Heart Rhythm, 2013,10(4):483-489.

[16] Kochhauser S, Khaykin Y, Beardsall J, et al. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens[J]. Can J Cardiol, 2014,30(12):1541-1546.

[17] Lakkireddy D, Reddy YM, Di BL, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry[J]. J Am Coll Cardiol, 2012,59(13):1168-1174.

[18] Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation[J]. J Cardiovasc Electrophysiol, 2013,24(8):861-865.

[19] Nagao T, Inden Y, Shimano M, et al. Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation[J]. Intern Med, 2015,54(10):1167-1173.

[20] Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation[J]. Pacing Clin Electrophysiol, 2013,36(2):172-179.

[21] Okishige K, Nakamura T, Aoyagi H, et al. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation[J]. J Cardiol, 2016.

[22] Snipelisky D, Kauffman C, Prussak K, et al. A comparison of bleeding complications postablation between warfarin and dabigatran[J]. J Interv Card Electrophysiol, 2012,35(1):29-33.

[23] Snipelisky D, Ray JC, Ung R, et al. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation[J]. J Interv Card Electrophysiol, 2014,41(3):231-236.

[24] Somani R, Mohajer K, Haley C, et al. The periprocedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation[J]. Cardiovasc Ther, 2014,32(5):198-201.
[25] Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation[J]. J Interv Card Electrophysiol, 2014,40(1):33-38.

[26] Yamaji H, Murakami T, Hina K, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation[J]. Clin Drug Investig, 2013,33(6):409-418.

[27] 江云东, 杨思进, 白雪, 等. 新型抗凝药达比加群酯对高龄持续性房颤导管射频消融术围术期的抗凝疗效及安全性评价[J]. 中国新药与临床杂志, 2015,(09):671-675.

[28] 潘文麒, 胡文瑛, 林长坚, 等. 达比加群酯在心房颤动消融围术期的应用[J]. 中华心律失常学杂志, 2015,19(2):104-107.

[29] 王璇, 王祖禄, 杨桂棠, 等. 达比加群酯用于心房颤动射频导管消融术后抗凝治疗有效性及安全性研究[J]. 中华心律失常学杂志, 2015,19(2):99-103.

[30] 周高俊, 杨兵, 郦明芳, 等. 达比加群酯在房性快速心律失常射频导管消融围术期抗凝治疗中的应用[J]. 中华心律失常学杂志, 2016,20(1)：60-63.

[31] Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RELY: randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran[J]. Am Heart J, [JP]2009,157(5):805-810.

[32] 张其银, 张敬云, 曾现生, 等. CHA2- DS2-VASc 评分与不同性别阵发性房颤患者导管射频消融疗效的相关性研究[J]. 实用心电学杂志, 2015,24(6)：431-436.

[33] Blech S, Ebner T, LudwigSchwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos, 2008,36(2):386-399.